Boehringer Ingelheim

Boehringer IngelheimThe Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

www.boehringer-ingelheim.com

Boehringer Ingelheim RSS Channel

Display # 
Title Published Date
New analysis shows only minority of COPD patients may benefit from inhaled corticosteroids 12 April 2016
Boehringer Ingelheim launches RE-COVERY DVT/PE™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate) 24 March 2016
European Commission confirms CMDh recommendation: Benefit/risk profiles of ambroxol and bromhexine products are favorable 25 January 2016
Boehringer Ingelheim and Arena Pharmaceuticals collaborate to advance research in schizophrenia 19 January 2016
Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer 22 December 2015
Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate) 26 November 2015
Boehringer Ingelheim will invest 11 billion euros in Research and Development in the next five years 12 November 2015
Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research 11 November 2015
Boehringer Ingelheim and BioMed X apply crowdsourcing to establish a team of scientists for identifying key epigenetic regulators of COPD 22 September 2015
International survey shows quality of patient-physician conversation at diagnosis linked to better patient outcomes 17 September 2015
Boehringer Ingelheim and Circuit Therapeutics announce new collaboration to discover novel medicines for obesity 14 August 2015
Patients reporting better quality of communication by their physician show improved self-care 08 June 2015
Eureka Therapeutics Inc. and Boehringer Ingelheim announce a collaboration to identify next generation antibodies for cancer treatment 26 May 2015
Boehringer Ingelheim acquires Pharmaxis' phase 1 anti-inflammatory drug candidate 19 May 2015
Boehringer Ingelheim positioned for future growth with product launches 28 April 2015
New international survey of lung cancer oncologists highlights underutilization of personalized treatments 20 April 2015
Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin 20 November 2014
Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy 24 September 2014
Boehringer Ingelheim Statement on Hepatitis C drug development 29 June 2014
Boehringer Ingelheim will make detailed clinical trial data available to the scientific community 14 May 2014

Most Popular Now

Brilinta preferred over clopidogrel…

AstraZeneca today confirmed that the American College of Cardiology (ACC) and American Heart Association (AHA) have released a treatment guideline on the duration of dual...

Read more

NIH launches large clinical trials …

Enrollment has begun in the first of two multinational clinical trials of an intravenously delivered investigational antibody for preventing HIV infection. Known as the A...

Read more

Pandemic influenza vaccine receives…

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europe...

Read more

Saxenda® demonstrated significant i…

Today, new data from the three-year part of the phase 3a SCALE™ (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at th...

Read more

World's first public dengue immuniz…

Sanofi and its vaccines global business unit Sanofi Pasteur announced today that the first public dengue immunization program has started in the Philippines. At a major l...

Read more

AstraZeneca and Eli Lilly and Compa…

AstraZeneca and Eli Lilly and Company today announced that AMARANTH, a Phase II/III study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in...

Read more

Vitamin D improves heart function, …

A daily dose of vitamin D3 improves heart function in people with chronic heart failure, a five-year University of Leeds research project has found. Dr Klaus Witte, from ...

Read more

Pfizer announces termination of pro…

Pfizer Inc. (NYSE: PFE) announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The deci...

Read more

New analysis shows only minority of…

Boehringer Ingelheim has announced a new publication showing that levels of white blood cells called eosinophils can help identify patients with COPD who may and may not ...

Read more

New insights in cancer therapy from…

Researchers in the group of Prof. Dr. Peter Vandenabeele (VIB/UGent) show that killed tumour cells can serve as a potent vaccine that stimulates the immune system to prev...

Read more

Researchers open the way to new tre…

In a recent paper published in Nature Communications, a group of Case Western University School of Medicine researchers presented their discovery of the full-length struc...

Read more

Physicians' knowledge about FDA app…

Since 2012, the FDA can designate a drug as a "breakthrough therapy" if preliminary clinical evidence - such as an improvement in a pharmacodynamic biomarker - suggests a...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]